Evolving strategies for renoprotection: Non-diabetic chronic renal disease

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 4, 2001, Pages 523-531

  Taal, Maarten W ^a   Brenner, Barry M ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASOPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROTECTION; PROTEIN RESTRICTION; PROTEINURIA; RENAL PROTECTION; REVIEW; SMOKING CESSATION; TREATMENT PLANNING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIET, PROTEIN-RESTRICTED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NEPRILYSIN; PROTEINURIA; RECEPTORS, ANGIOTENSIN; SMOKING CESSATION;

EID: 0034917492     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200107000-00007     Document Type: Review

References (102)

1. A simple method for estimating progression of chronic renal failure
2. Chronic progressive renal disease: Rate of change of serum creatinine
3. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats
4. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
5. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation
6. Chronic effects of dietary protein in the rat with intact and reduced renal mass
7. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
8. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
9. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells
10. 1 receptors
11. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
12. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
13. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis
14. Effect of angiotensin II on macrophage functions
15. Angiotensin II stimulation of granuloma macrophage phagocytosis and actin polymerization in murine schistosomiasis mansoni
16. Activation of human peripheral monocytes by angiotensin II
17. Role of aldosterone in the remnant kidney model in the rat
18. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
19. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study
20. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study
21. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis
22. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
23. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
24. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
25. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
26. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR
27. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
28. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
29. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment
30. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
31. Blood pressure and end-stage renal disease in men
32. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
33. Mechanisms underlying renoprotection during renin-angiotensin system blockade
34. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
35. Pathophysiology of progressive nephropathies
36. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins
37. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein
38. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation
39. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
40. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria
41. Lipoprotein abnormalities in chronic renal failure and dialysis patients
42. Predictors of progression of renal disease in the Modification of Diet in Renal Disease Study
43. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency
44. Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy
45. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia
46. Relation between serum cholesterol and diabetic nephropathy
47. Serum lipids in patients with chronic renal failure on long-term, protein-restricted diets
48. Actions of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors
49. LDL stimulates mesangial fibronectin production and chemoattractant expression
50. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury
51. Renal injury of diet-induced hypercholesterolemia in rats
52. Pharmacologic treatment of hyperlipidemia reduces injury in rat 5/6 nephrectomy model of chronic renal failure
53. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
54. Lovastatin retards the progression of established glomerular disease in obese Zucker rats
55. Lovastatin reduces glomerular macrophage influx and monocyte chemoattractant protein-1 mRNA in nephrotic rats
56. Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients
57. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure
58. Treatment of hyperlipidemia in the nephrotic syndrome: The effects of pravastatin therapy
59. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria
60. Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type I (insulin-dependent) diabetes
61. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes
62. Microalbuminuria: A marker to increased renal and cardiovascular risk in diabetes mellitus
63. Smoking as a risk factor for end-stage renal failure in men with primary renal disease
64. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking
65. Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies
66. Serine protease angiotensin II systems
67. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
68. Widespread tissue distribution of human chymase
69. Angiotensin I converting enzyme and chymase in cardiovascular tissues
70. 2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog
71. 2 receptors
72. Angiotensin II receptors
73. 2 receptor mRNA during development of rat kidney and adrenal gland
74. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men
75. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
76. The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats
77. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
78. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study
79. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
80. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
81. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
82. Clinical safety and tolerability of losartan
83. Effects of modulators of the renin-angiotensin-aldosterone system on cough
84. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide
85. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
86. Antiproteinuric effect of losartan in patients with chronic renal diseases
87. Randomised controlled trial of dual blockade of renin-angiotensin system in pateints with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
88. Vasopeptidase inhibition: A new concept in blood pressure management
89. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
90. Effects of omapatrilat in low, normal, and high renin experimental hypertension
91. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
92. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone in rats with established nephropathy after 5/6 nephrectomy
93. Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression
94. Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids
95. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model
96. Focal glomerulosclerosis in the remnant kidney model - An inflammatory disease mediated by cytokines
97. Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II
98. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system
99. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney
100. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney
101. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats
102. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals